Business Context and Reporting Period
This Form 8-K Current Report was filed by CytoSorbents Corporation on May 30, 2017, regarding an event dated May 23, 2017. The filing announces the appointment of Eric R. Mortensen, M.D., Ph.D., as the Company's Chief Medical Officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation and employment terms.
- Base Salary: $330,000 per year for the new Chief Medical Officer.
- Equity Compensation: Eligible under the CytoSorbents Corporation 2014 Long-Term Incentive Plan.
- Change of Control: Entitled to an incentive compensation award upon a Change of Control, terms to be determined by the Compensation Committee.
Material Changes
The primary material change is the addition of Dr. Mortensen to the executive leadership team. He brings extensive experience from Pfizer (2011–2017), GlaxoSmithKline (2001–2008), and Merck Research Laboratories (1996–2001), specifically in inflammation, immunology, and late-stage clinical development.
Outlook, Risks, and Unusual Items
Employment Terms: The Employment Agreement has an initial term from June 1, 2017, to December 31, 2019. It automatically renews for one-year terms unless either party provides written notice of non-renewal at least 60 days prior to the end of the term.
Compensation Review: The base salary is subject to annual review by the Compensation Committee of the Board of Directors.
Covenants: The agreement includes customary non-competition, non-solicitation, confidentiality, and work-made-for-hire provisions.
Investor Verification Checklist
- Verify the impact of the new Chief Medical Officer on the Company's clinical development pipeline, particularly in inflammatory diseases.
- Review the specific terms of the "Change of Control" incentive award in the attached Employment Agreement (Exhibit 10.1).
- Confirm the dilution impact of the equity compensation granted under the 2014 Long-Term Incentive Plan.
- Assess the strategic alignment of Dr. Mortensen's background with CytoSorbents' current product portfolio.